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 Abstract 
 
Objectives:  Integrase inhibitors have emerged as an important new antiretroviral agent.  We 
examined polymorphisms in integrase sequences from 342 antiretroviral-naïve individuals 
from the Western Australian and Swiss HIV Cohort Studies, to examine site-specific 
interactions between HIV-1 subtype, human leukocyte antigen (HLA)-associated immune 
selection and integrase inhibitor resistance. 
 
Methods:  Standard bulk sequencing and sequence based typing were used to generate 
integrase sequences and 4-digit HLA genotypes.  Viral residues were examined with respect 
to published drug resistance mutations and a reference dataset of CD8 T-cell escape 
mutations.  Elispot-assays were performed for functional analysis of predicted epitopes. 
 
Results: In both predominantly subtype-B cohorts, twelve of 38 sites that mediate integrase 
inhibitor resistance were absolutely conserved including the primary resistance mutations.  
There were 18 codons with non-primary drug resistance associated substitutions at rates up 
to 58.8%.  V72I and V201I, were the most common resistance mutations and isoleucine was 
associated for both with a significantly higher viral load than valine (p=0.025, mean delta log 
VL=0.21 at codon 72, p=0.00003, mean delta log VL=0.39 at codon 201).   Five viral 
residues were potentially subject to dual drug and HLA associated immune selection in 
which both selective pressures either drove the same amino acid substitution (codons 72, 
157, 163) or HLA alleles were associated with an alternative polymorphism that would alter 
the genetic barrier to resistance (125 and 193) (Tab.1).   
Tab.1 
human leukocyte epitope position amino acid drug resistance
antigen allele epitope in integrase position in integrase non-adapted adapted associated mutation
A*0206 HLEGKVILV 67 - 75 72 V I I
B*5701, B*5703, B*5801 STTVKAACWW 123 - 132 125 T A K
A*3303 ELKKIIGQVR 157 - 166 157 E Q Q
A*3303 ELKKIIGQVR 157 - 166 163 G E/A A, E, Q, T, R
B*2705 KRKGGIGGY 186 - 194 193 G E R  
 
The common polymorphism T125A increased the mutational barrier to the resistance 
mutation T125K and was both characteristic of non-subtype-B and associated with carriage 
of HLA-B*57/*5801. 
Conclusions:  In an antiretroviral-naïve population-based cohort, primary integrase inhibitor 
resistance mutations were not detected in keeping with these being sites of significant 
functional, catalytic or structural importance.  Viral polymorphisms due to immune selection 
and/or associated with non-subtype-B and particular HLA alleles may alter the genetic 
barrier to some non-primary resistance associated mutations.  
